ArticleInternational journal of medical sciences2013
Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients: a retrospective-cohort study.
Article in International journal of medical sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 4 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Guideline
- [Guidelines for diagnosis and treatment of liver failure (2024 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Guideline
- A Systematic Review of Population Pharmacokinetics, Safety, and Factors Influencing Trough Concentrations of Voriconazole in Asian Patients with Liver Dysfunction.Drug design, development and therapy · 2025Pooled it
- Age difference of patients with and without invasive aspergillosis: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Novel Diagnostic Marker Interleukin-33 for Invasive Pulmonary Aspergillosis in Acute-on-Chronic Liver Failure: A Proof-of-Concept Prospective Study.Infectious diseases and therapy · 2026Article
- Serum Interleukin-8 for Differentiating Invasive Pulmonary Aspergillosis from Bacterial Pneumonia in Patients with HBV-Associated Acute-on-Chronic Liver Failure.Journal of clinical and translational hepatology · 2026Article
- Unmasking Invasive Pulmonary Aspergillosis: Insights From a Case Series at a Tertiary Care Center.Cureus · 2025Article
- Phase characteristics and risk factors of acute-on-chronic liver failure with invasive pulmonary aspergillosis.BMC infectious diseases · 2025Article
- Invasive Fungal Infections in Acute Decompensation of Cirrhosis: Epidemiology, Predictors of 28-Day Mortality, and Outcomes.Indian journal of microbiology · 2025Article
- Safety and recommendation of voriconazole for invasive pulmonary aspergillosis in severe liver disease patients: a retrospective cohort study.BMC infectious diseases · 2025Article
- Invasive Pulmonary Aspergillosis in Patients with HBV-Related Acute on Chronic Liver Failure.Journal of fungi (Basel, Switzerland) · 2024Article
- Characteristics and risk factors for invasive fungal infection in hospitalized patients with acute-on-chronic hepatitis B liver failure: a retrospective cohort study from 2010 to 2023.Frontiers in microbiology · 2024Article
- Article
- Pathogenicity and virulence ofVirulence · 2023Review
- DectiSomes: C-type lectin receptor-targeted liposomes as pan-antifungal drugs.Advanced drug delivery reviews · 2023Review
- Case Report and Clinical Reasoning: Fulminant Liver Failure and Invasive Aspergillosis Following Ocrelizumab Treatment in a 21 Year-Old Woman.The Neurohospitalist · 2023Article
- Article
- Therapeutic Potential of Green Synthesized Gold Nanoparticles Using Extract ofJournal of fungi (Basel, Switzerland) · 2022Article
- [Consensus on diagnosis and treatment of invasive fungal infection in patients with severe liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- The Mechanisms of Systemic Inflammatory and Immunosuppressive Acute-on-Chronic Liver Failure and Application Prospect of Single-Cell Sequencing.Journal of immunology research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundInvasive pulmonary aspergillosis (IPA) in acute-on-chronic liver failure (ACLF) patients is associated with a high mortality. But the clinical characteristics of and the risk factors for IPA among patients with ACLF remains unclear. This study was aimed at assessing clinical manifestation, the risk factors and antifungal medications for as well as the mortality due to IPA in ACLF patients at the First Affiliated Hospital, College of Medicine, Zhejiang University. PATIENTS AND
methodsPatients with ACLF who were diagnosed with proven or probable IPA by clinical and laboratory parameters from 1 December 2008 to 1 May 2012 were retrospectively evaluated to determine the risk factors for IPA and the clinical outcomes. The follow-up ended on 30 July 2012. Multivariate analysis was performed to identify the risk factors for mortality and the development of IPA.
resultsIn total, 787 patients with ACLF were enrolled, and 39 of these patients developed IPA. Thirty seven of these 39 patients died in spite of treatment with antifungal drugs. Controls included 48 patients who did not have a pulmonary infection. The survival rate of patients with IPA was significantly lower than that of those without IPA. IPA was found to be independently associated with age (p = 0.021), encephalopathy (p = 0.002), and steroid use (p = 0.000). There was significant difference in the prognosis between the patients treated with either voriconazole or itraconazole and those without antifungal treatment.
conclusionsPatients with ACLF and IPA have a high mortality rate. Patients with ACLF who present with encephalopathy should avoid steroids, as they increase the mortality rate. Azoles may prolong the survival time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.